Revance Therapeutics Inc (NAS:RVNC)
$ 2.85 -0.04 (-1.38%) Market Cap: 296.11 Mil Enterprise Value: 500.56 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 13, 2019 / 05:20PM GMT
Release Date Price: $15.07 (-0.66%)
Matthew Weston;dit Suisse AG
CrÃ;Research Division - MD and Co-Head of European Pharmaceutical Equity Research

© -

Good morning, everyone. I'm happy to introduce our next guest from Revance Therapeutics. Please welcome CFO, Toby Schilke.

Tobin C. Schilke
Revance Therapeutics, Inc. - CFO & Principal Accounting Officer

Thanks, Matt, and thanks, Crédit Suisse, for hosting us today. It's my privilege to give you an overview of Revance Therapeutics. Again, my name is Toby Schilke. I'm the CFO of Revance Therapeutics.

This presentation contains forward-looking statements. I encourage you to read them on our website in detail and also the risk factors on Form 10-K and 10-Q of our recent SEC filings.

It's an exciting time to be at Revance. We're at the cusp of considerable amount of value-creation activities, and we've most recently announced the new CEO, Mark Foley from ZELTIQ Aesthetics. So very exciting time to be commercializing DAXI, a differentiated, longer-lasting neuromodulator in aesthetics that we hope to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot